| 1997/98 |
< 50 years
n=67 |
P |
60-69 years
n=70 |
P |
≥70 years
n = 89 |
| PI %
(n) |
19.78±16.84
(63) |
=0.01 |
13.04±12.83
(70) |
ns |
13.38±12.30
(80) |
| SSI %
(n) |
23.37±17.80
(57) |
<0.05 |
17.36±10.91
(67) |
ns |
14.68±11.86
(80) |
| ALNM+
fraction %
(n) |
0.19±0.28 (56) |
<0.05 |
0.11±0.18 (73) |
ns |
0.13±0.28 (48) |
| Cyclin-A %
(n) |
16.60±15.26
(67) |
< 0.05 |
11.64±13.34
(70) |
ns |
9.26±9.46 (84) |
| Ki67 %
(n) |
32.53±24.30 (66) |
ns |
25.81±25.31 (70) |
ns |
22.4±22.7 (84) |
| Stage I %
(n)
|
21.9 (64) |
<0.05 |
38.4
(68) |
ns |
22,4
(84) |
| Stage IIB % (n)
|
17.2 (64) |
<0.01 |
2.9 (70) |
ns |
9,4 (84) |
Seven parameters–proliferation index (PI), Stemline Scatter Index (SSI); axillary
lymph node metastasis (ALNM); cyclin-A, Ki67 and tumor stage I and IIB– were
analyzed.. All parameters but Ki67 significantly differed in the younger group.
No significant difference appeared against the older patient group. Total number
of patients per age interval is shown in the top line of the table. Because the
parameters can have some missing values the n-values are also shown within the
table. For cell cycle parameters the P-value is estimated using the mean values ±
SD. For stage I and stage IIB tumors the percentage in relation to the total patient
number (n=64) is shown in the table. The P-value is estimated by comparing the
percentages related to the n-values. |